We are live on !
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
Turnover
52.63%
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$34.7M
AUM Growth
-$282M
(-89%)
Cap. Flow
-$261M
Cap. Flow % of AUM
Cap. Flow %
-752.45%
Top 10 Holdings %
Top 10 Hldgs %
75.76%
Holding
38
New
7
Increased
–
Reduced
18
Closed
13
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Radius Health, Inc.
RDUS
|
+$1.91M |
| 2 |
Gilead Sciences
GILD
|
+$1.57M |
| 3 |
McKesson
MCK
|
+$1.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$538K |
| 5 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$347K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$24.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.7M |
| 3 |
Sanofi
SNY
|
+$17.1M |
| 4 |
Viatris
VTRS
|
+$16.1M |
| 5 |
Pfizer
PFE
|
+$15.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Miscellaneous | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Merck
MRK
$354B
| $6.52M | 18.82% |
112,591
-183,385
| -62% | -$10.3M |
2018 Q1
1 quarter
|
|
|
2
Sanofi
SNY
$94.8B
| $3.07M | 8.87% |
76,836
-434,610
| -85% | -$17.1M |
2017 Q3
3 quarters
|
|
|
3
Viatris
VTRS
$21B
| $3.01M | 8.69% |
83,370
-410,450
| -83% | -$16.1M |
2017 Q4
2 quarters
|
|
4
Cigna
CI
$78.9B
| $2.96M | 8.53% |
17,392
-74,408
| -81% | -$12.9M |
2018 Q1
1 quarter
|
|
|
5
AstraZeneca
AZN
$254B
| $2.51M | 7.23% |
35,700
-343,155
| -91% | -$24.7M |
2018 Q1
1 quarter
|
|
|
6
Regeneron Pharmaceuticals
REGN
$80.5B
| $1.8M | 5.2% |
5,220
-56,500
| -92% | -$17.7M |
2017 Q3
3 quarters
|
|
|
7
DELISTED
Radius Health, Inc.
RDUS
| $1.78M | 5.15% |
+60,521
| New | +$1.91M |
2018 Q2
0 quarters
|
|
|
8
Gilead Sciences
GILD
$190B
| $1.58M | 4.56% |
+22,300
| New | +$1.57M |
2018 Q2
0 quarters
|
|
9
CVS Health
CVS
$119B
| $1.57M | 4.52% |
24,330
-96,500
| -80% | -$6.36M |
2017 Q4
2 quarters
|
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $1.45M | 4.2% |
8,723
-83,649
| -91% | -$13.4M |
2017 Q3
3 quarters
|
|
|
ALDR
11
DELISTED
Alder Biopharmaceuticals
ALDR
| $1.35M | 3.9% |
85,558
-737,332
| -90% | -$11.2M |
2015 Q3
11 quarters
|
|
12
AnaptysBio
ANAB
$1.47B
| $1.14M | 3.27% |
15,970
-9,230
| -37% | -$774K |
2018 Q1
1 quarter
|
|
|
13
McKesson
MCK
$118B
| $1M | 2.89% |
+7,500
| New | +$1.1M |
2018 Q2
0 quarters
|
|
14
DELISTED
Theravance Biopharma
TBPH
| $621K | 1.79% |
27,397
-160,459
| -85% | -$3.81M |
2017 Q3
3 quarters
|
|
15
MiMedx Group
MDXG
$639M
| $543K | 1.57% |
85,050
-817,050
| -91% | -$5.82M |
2017 Q4
2 quarters
|
|
|
16
Alnylam Pharmaceuticals
ALNY
$31.2B
| $534K | 1.54% |
+5,425
| New | +$538K |
2018 Q2
0 quarters
|
|
|
ELGX
17
DELISTED
Endologix Inc
ELGX
| $517K | 1.49% |
9,142
-122,549
| -93% | -$6.22M |
2017 Q3
3 quarters
|
|
|
CNCE
18
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $502K | 1.45% |
29,821
-169,318
| -85% | -$3.29M |
2014 Q3
15 quarters
|
|
|
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $485K | 1.4% |
11,123
-116,441
| -91% | -$5M |
2018 Q1
1 quarter
|
|
20
TG Therapeutics
TGTX
$8.16B
| $415K | 1.2% |
31,594
-444,324
| -93% | -$6.11M |
2017 Q1
5 quarters
|
|
21
Protagonist Therapeutics
PTGX
$8.7B
| $412K | 1.19% |
61,304
-114,686
| -65% | -$880K |
2017 Q2
4 quarters
|
|
|
FOMX
22
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $338K | 0.98% |
+67,429
| New | +$347K |
2018 Q2
0 quarters
|
|
23
United Therapeutics
UTHR
$23.3B
| $297K | 0.86% |
2,625
-44,375
| -94% | -$4.88M |
2018 Q1
1 quarter
|
|
24
Prothena Corp
PRTA
$435M
| $249K | 0.72% |
+17,090
| New | +$338K |
2018 Q2
0 quarters
|
|
|
25
CALL
Viatris
VTRS
$21B
| $1K | ﹤0.01% |
+2,125
| New | +$83.4K |
2018 Q2
0 quarters
|
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, Senzar Asset Management held 38 positions worth $34.7M, down 89% from $317M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Senzar Asset Management withdrew a net $261M in Q2 2018, closing 13 positions and reducing 18 holdings. Its most notable exit was Pfizer, an estimated $15.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Senzar Asset Management opened a new position in Radius Health, Inc. worth $1.78M.
- Senzar Asset Management's largest Q2 2018 buy was Radius Health, Inc.: 60,521 shares worth $1.78M.
- Senzar Asset Management's biggest Q2 2018 reduction was AstraZeneca, cutting an estimated $24.7M.
- Senzar Asset Management fully exited Pfizer in Q2 2018, selling an estimated $15.5M.
- Senzar Asset Management's ten largest holdings make up 76% of its $34.7M portfolio in Q2 2018.
- Senzar Asset Management opened 7 new positions and closed 13 in Q2 2018.
- Senzar Asset Management's portfolio value fell 89% quarter-over-quarter to $34.7M.
Based on Senzar Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.